Literature DB >> 6411921

Blood and serum concentrations of gold after a single dose of auranofin in children with juvenile rheumatoid arthritis.

E H Giannini, D A Person, E J Brewer, D B Parks.   

Abstract

Three children with juvenile rheumatoid arthritis were given a single oral dose of approximately 0.1 mg/kg of auranofin. Blood concentrations up to 49 ng/ml were detectable at 24 h (earliest sample) and remained detectable for at least 2 weeks (final sample). Disappearance of measurable gold from both the blood and serum appeared to be linear through time. None of the patients experienced significant laboratory abnormalities nor adverse reactions. Gold levels attained in these children were somewhat lower than those seen in adults administered an equivalent dose.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411921

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

1.  A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome.

Authors:  Aminah Jatoi; Megan E Grudem; Travis J Dockter; Matthew S Block; Jose C Villasboas; Angelina Tan; Erin Deering; Pashtoon M Kasi; Aaron S Mansfield; Juliana Perez Botero; Scott H Okuno; Deanne R Smith; Alan P Fields
Journal:  Support Care Cancer       Date:  2016-11-12       Impact factor: 3.603

Review 2.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.